Hikal Limited

BSE:524735 Stock Report

Market Cap: ₹48.4b

Hikal Valuation

Is 524735 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 524735 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 524735 (₹387.65) is trading above our estimate of fair value (₹2.41)

Significantly Below Fair Value: 524735 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 524735?

Key metric: As 524735 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 524735. This is calculated by dividing 524735's market cap by their current earnings.
What is 524735's PE Ratio?
PE Ratio64.9x
Earnings₹736.02m
Market Cap₹48.36b

Price to Earnings Ratio vs Peers

How does 524735's PE Ratio compare to its peers?

The above table shows the PE ratio for 524735 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average39.3x
JSLL Jeena Sikho Lifecare
57xn/a₹48.0b
AARTIPHARM Aarti Pharmalabs
24.5xn/a₹55.9b
509079 Gufic Biosciences
48.2xn/a₹42.2b
524348 Aarti Drugs
27.5x31.5%₹41.9b
524735 Hikal
64.9x49.2%₹47.8b

Price-To-Earnings vs Peers: 524735 is expensive based on its Price-To-Earnings Ratio (64.9x) compared to the peer average (39.3x).

Price to Earnings Ratio vs Industry

How does 524735's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
INDSWFTLAB Ind-Swift Laboratories
1.6xn/aUS$71.82m
524652 Ind-Swift
2xn/aUS$13.29m
No more companies available in this PE range
524735 64.9xIndustry Avg. 32.2xNo. of Companies19PE020406080100+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 524735 is expensive based on its Price-To-Earnings Ratio (64.9x) compared to the Indian Pharmaceuticals industry average (32.2x).

Price to Earnings Ratio vs Fair Ratio

What is 524735's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

524735 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio64.9x
Fair PE Ratio55.1x

Price-To-Earnings vs Fair Ratio: 524735 is expensive based on its Price-To-Earnings Ratio (64.9x) compared to the estimated Fair Price-To-Earnings Ratio (55.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 524735 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₹387.65
₹435.00
+12.2%
3.4%₹450.00₹420.00n/a2
Nov ’25₹383.85
₹425.00
+10.7%
1.2%₹430.00₹420.00n/a2
Oct ’25₹371.40
₹425.00
+14.4%
1.2%₹430.00₹420.00n/a2
Sep ’25₹328.40
₹397.50
+21.0%
8.2%₹430.00₹365.00n/a2
Aug ’25₹338.00
₹347.50
+2.8%
5.0%₹365.00₹330.00n/a2
Jul ’25₹346.05
₹347.50
+0.4%
5.0%₹365.00₹330.00n/a2
Jun ’25₹284.90
₹347.50
+22.0%
5.0%₹365.00₹330.00n/a2
Dec ’24₹284.30
₹328.00
+15.4%
6.7%₹350.00₹306.00n/a2
Nov ’24₹280.15
₹353.00
+26.0%
13.3%₹400.00₹306.00₹383.852
Oct ’24₹295.95
₹353.00
+19.3%
13.3%₹400.00₹306.00₹371.402
Sep ’24₹307.55
₹353.00
+14.8%
13.3%₹400.00₹306.00₹328.402
Aug ’24₹290.50
₹353.00
+21.5%
13.3%₹400.00₹306.00₹338.002
Jul ’24₹313.40
₹353.00
+12.6%
13.3%₹400.00₹306.00₹346.052
Jun ’24₹310.55
₹353.00
+13.7%
13.3%₹400.00₹306.00₹284.902
May ’24₹295.55
₹387.50
+31.1%
3.2%₹400.00₹375.00₹303.402
Apr ’24₹281.90
₹387.50
+37.5%
3.2%₹400.00₹375.00₹275.752
Mar ’24₹300.20
₹387.50
+29.1%
3.2%₹400.00₹375.00₹278.502
Feb ’24₹350.60
₹350.00
-0.2%
5.7%₹370.00₹330.00₹296.452
Jan ’24₹410.25
₹332.67
-18.9%
8.9%₹370.00₹298.00₹300.453
Dec ’23₹339.65
₹332.67
-2.1%
8.9%₹370.00₹298.00₹284.303
Nov ’23₹332.05
₹321.00
-3.3%
11.9%₹375.00₹290.00₹280.153

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Bal Pharma

₹2.1b

Manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally.

BALPHARMA

₹134.50

7D

11.6%

1Y

27.4%

Mercury Laboratories

₹1.1b

Develops, manufactures, markets, distributes, and sells pharmaceutical drugs, medicines, and formulations for mother and child healthcare in India and internationally.

538964

₹911.45

7D

-3.5%

1Y

18.7%

Venus Remedies

₹3.9b

Engages in the pharmaceutical business in India and internationally.

VENUSREM

₹298.65

7D

-1.3%

1Y

-16.9%